European Mid-Sized Pharma Firms Rapidly Acquire U.S. Biopharma Assets: Is a Cross-Border M&A Wave Underway?
From late April to early May, three European mid-sized pharmaceutical companies made successive moves in the U.S. biopharma sector: Chiesi acquired KalVista, Angelini bought Catalyst for about $4.1 billion, and Leo Pharma acquired Replay. The three sources point to a series of consecutive deals within the same time window, but they do not provide enough information to confirm whether this amounts to a “systematic buying trend” or to fully verify every deal term.